Giovanetti and colleagues (113) identified a significant correlation between the Arg399 polymorphism of XRCC1 and a worse response to platinum-based therapeutic regimens (113), indicating that XRCC1 could be used in PDA to predict response to platinum-based therapies as in other cancers. The gene discussed is XRCC1; the disease is Patent ductus arteriosus.